PE20090151A1 - Derivados de pirimidinona y metodos para su uso - Google Patents

Derivados de pirimidinona y metodos para su uso

Info

Publication number
PE20090151A1
PE20090151A1 PE2008000681A PE2008000681A PE20090151A1 PE 20090151 A1 PE20090151 A1 PE 20090151A1 PE 2008000681 A PE2008000681 A PE 2008000681A PE 2008000681 A PE2008000681 A PE 2008000681A PE 20090151 A1 PE20090151 A1 PE 20090151A1
Authority
PE
Peru
Prior art keywords
fluorophenyl
cycloalkyl
aryl
phenyl
alkyl
Prior art date
Application number
PE2008000681A
Other languages
English (en)
Inventor
Craig D Boyle
Santhosh Francis Neelamkayil
Samuel Chackalamannil
Bernard R Neustadt
Jinsong Hao
Unmesh G Shah
Joel Harris
Hong Liu
Andrew W Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090151A1 publication Critical patent/PE20090151A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDINONA DE FORMULA I, DONDE J Y G SON UN ENLACE SIMPLE, -C(R10)(R11)- O -C(R10)(R11)-C(R10)(R11)-, DE MANERA TAL QUE i)SI J ES -C(R10)(R11)-, ENTONCES G ES -C(R10)(R11)- O -C(R10)(R11)-C(R10)(R11)-, Y ii)SI J ES -C(R10)(R11)-C(R10)(R11)-, ENTONCES G ES UN ENLACE SIMPLE; R ESTA AUSENTE O ES O; R1 ES H, -N(R9)2, -S(O)pR7, -(ALQUILEN)n-CICLOALQUILO, ENTRE OTROS; R2 ES FENILO, 4-FLUOROFENILO, CICLOBUTILO, ENTRE OTROS; R3 ES FENILO, PIRIDILO, 4-FLUOROFENILO, ENTRE OTROS; R4 ES H, 1,2,4-OXADIAZOLILO, HETEROARILO, ENTRE OTROS; R7 ES ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS; R9, R10 Y R11 SON INDEPENDIENTEMENTE H, ALQUILO, -(ALQUILEN)n-ARILO, ENTRE OTROS; n ES 0 O 1; p ES DE 0 A 2. SON SELECCIONADOS II, III, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA, QUE PUEDE CONTENER ADICIONALMENTE OTROS PRINCIPIOS ACTIVOS TALES COMO, MEGLITINIDA, SERGLIFLOZINA, LEPTINA, ORLISTAT, SITAGLIPTINA, ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE GPR119, POR LO QUE SON DE UTILIDAD EN EL TRATAMIENTO Y/O PREVENCION DE OBESIDAD, DIABETES, ENFERMEDADES CADIOVASCULARES, ENTRE OTROS
PE2008000681A 2007-04-20 2008-04-18 Derivados de pirimidinona y metodos para su uso PE20090151A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92545007P 2007-04-20 2007-04-20
US95334207P 2007-08-01 2007-08-01

Publications (1)

Publication Number Publication Date
PE20090151A1 true PE20090151A1 (es) 2009-02-26

Family

ID=39655056

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000681A PE20090151A1 (es) 2007-04-20 2008-04-18 Derivados de pirimidinona y metodos para su uso

Country Status (11)

Country Link
US (1) US20100190687A1 (es)
EP (1) EP2148869A1 (es)
JP (1) JP2010524940A (es)
CN (1) CN102015677A (es)
AR (1) AR066121A1 (es)
CA (1) CA2684633A1 (es)
CL (1) CL2008001126A1 (es)
MX (1) MX2009011358A (es)
PE (1) PE20090151A1 (es)
TW (1) TW200900403A (es)
WO (1) WO2008130581A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008038768A1 (ja) * 2006-09-28 2010-01-28 大日本住友製薬株式会社 二環性ピリミジン構造を有する化合物及びそれを含有する医薬組成物
WO2010095767A1 (en) * 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102234287B (zh) 2010-04-26 2015-08-05 上海阳帆医药科技有限公司 硝基咪唑类化合物、其制备方法和用途
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN102464661B (zh) * 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
JP2016222621A (ja) * 2015-06-02 2016-12-28 学校法人九州文化学園 メラニン合成促進組成物
WO2017021805A1 (en) 2015-07-31 2017-02-09 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Magl阻害薬としての複素環式スピロ化合物
CN110452157B (zh) * 2018-12-28 2020-11-03 广州市朗启医药科技有限责任公司 常山酮及其中间体的合成方法
CA3132531A1 (en) * 2019-03-14 2020-09-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
EP4161643A1 (en) * 2020-06-05 2023-04-12 Pathios Therapeutics Limited N-(phenylaminocarbonyl) tetrahydro-isoquinolines and related compounds as modulators of gpr65
CA3181982A1 (en) * 2020-06-09 2021-12-16 David A. Scott Allosteric egfr inhibitors and methods of use thereof
WO2022053010A1 (en) * 2020-09-11 2022-03-17 Janssen Sciences Ireland Unlimited Company Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
WO2022087011A1 (en) * 2020-10-21 2022-04-28 Aligos Therapeutics, Inc. Bicyclic compounds
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264439A (en) * 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
US5240938A (en) * 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5409926A (en) * 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
ES2280435T3 (es) * 2000-12-01 2007-09-16 Astellas Pharma Inc. Metodo de exploracion de remedios para la diabetes.
JP2006518763A (ja) * 2003-02-24 2006-08-17 アリーナ ファーマシューティカルズ, インコーポレイテッド グルコース代謝のモジュレーターとしてのフェニル−およびピリジルピペリジン誘導体
EP1951244A4 (en) * 2005-11-22 2010-08-25 Glaxosmithkline Llc CALCILYTIC COMPOUNDS
JPWO2008038768A1 (ja) * 2006-09-28 2010-01-28 大日本住友製薬株式会社 二環性ピリミジン構造を有する化合物及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
MX2009011358A (es) 2009-11-05
EP2148869A1 (en) 2010-02-03
CL2008001126A1 (es) 2008-10-24
CA2684633A1 (en) 2008-10-30
WO2008130581A1 (en) 2008-10-30
AR066121A1 (es) 2009-07-22
TW200900403A (en) 2009-01-01
US20100190687A1 (en) 2010-07-29
CN102015677A (zh) 2011-04-13
JP2010524940A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
TW200602056A (en) Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
NO20055688L (no) Organiske forbindelser
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
TW200612936A (en) Indole derivatives
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
SE0202133D0 (sv) Novel compounds
GB0305152D0 (en) Organic compounds
TW200833670A (en) Novel compounds 569
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
HUP0302248A2 (hu) Cianopirrolidin-származékok és az ezeket tartalmazó gyógyászati készítmények
BRPI0510666A (pt) compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
TW200626553A (en) Novel compounds
TW200801003A (en) Novel compounds
TW200738666A (en) Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BRPI0519292A2 (pt) compostos orgÂnicos
TW200740781A (en) Novel compounds
TW200510317A (en) Caspase inhibitors and uses thereof
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
SE0303541D0 (sv) New compounds

Legal Events

Date Code Title Description
FD Application declared void or lapsed